Metropolis Healthcare Q1 FY27 Results Analysis: PAT Surges 26%, Cost Ratio Improves 113 bps

Metropolis Healthcare Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 450.21 Cr (+16.62% YoY) and PAT growth of +25.76% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Revenue grew 16.6% YoY and PAT grew 25.8%, with EBITDA margin of 25.8% within the company's target range. Cost management was excellent, led by a 113 bps improvement in cost of materials ratio. However, subsidiary contributions declined and no explicit full-year guidance was provided, limiting near-term catalysts.

Key Investment Insights

Key Positives

• Revenue grew 16.62% YoY to Rs.450.21 crore
• PAT (attributable to owners) grew 25.76% YoY to Rs.56.67 crore
• EBITDA margin expanded 63 bps YoY to 25.83%, within the 25-26% target range
• Cost of materials ratio improved 113 bps YoY to 19.35%
• EBITDA grew 19.56% YoY, outpacing revenue growth and demonstrating operating leverage

Risk Factors

• Other income fell 32.12% YoY to Rs.5.10 crore, reducing total income growth
• Subsidiary contribution to PAT declined from Rs.9.70 crore in Q1FY26 to Rs.6.01 crore in Q1FY27, indicating thin margins at acquired entities
• Finance costs rose 18.88% YoY to Rs.6.18 crore, tracking an expanded revenue base